Inhalation is an efficient way to deliver aerosol drugs such as bronchodilators when treating patients for asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD).
The pharmaceutical industry is facing continuous challenges to find more efficient and less costly aerosol drug delivery devices. Importantly, those devices have to be easy to use, convenient and capable of producing small-sized aerosol particles.
Electronic nicotine delivery systems (ENDS), of which electronic cigarettes are the most common prototype, deliver an aerosol by heating a solution that users inhale. Due to its capabilities, the e-cigarette can be easily considered as an alternative to current delivery devices.
After evaluation, ENDS have been reported to be very efficient and a good alternative to current delivery devices. The Coriolis µ, Bertin’s innovative air sampler, was used to qualify the emitted drug mass per puff under a realistic puffing behavior.